American Society of Hirudotherapy

Antiphospholipid syndrome, antiphospholipid antibodies, and stroke

Review published in International journal of stroke : official journal of the International Stroke Society (2023)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical LiteratureDrug DevelopmentMittal et al. · International journal of stroke : official journal of the International Stroke Society, 2023

Abstract

Antiphospholipid syndrome (APS) is a prothrombotic autoimmune disease with heterogeneous clinicopathological manifestations and is a well-established cause of acute ischemic stroke (AIS) and transient ischemic attack (TIA), particularly in younger patients. There is growing recognition of a wider spectrum of APS-associated cerebrovascular lesions, including white matter hyperintensities, cortical atrophy, and infarcts, which may have clinically important neurocognitive sequalae. Diagnosis of APS-associated AIS/TIA requires expert review of clinical and laboratory information. Management poses challenges, given the potential for substantial morbidity and recurrent thrombosis, additional risk conferred by conventional cardiovascular risk factors, and limited evidence base regarding optimal antithrombotic therapy for secondary prevention. In this review, we summarize key features of APS-associated cerebrovascular disorders, with focus on clinical and laboratory aspects of diagnostic evaluation. The current status of prognostic markers is considered. We review the evidence base for antithrombotic treatment in APS-associated stroke and discuss uncertainties, including the optimal intensity of anticoagulation and efficacy of direct oral anticoagulants. Clinical practice recommendations are provided, covering antithrombotic treatment, supportive management, and options for anticoagulant-refractory cases, and we highlight the benefits of adopting a considered, multidisciplinary team approach.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHumansAntiphospholipid SyndromeStrokeIschemic StrokeFibrinolytic AgentsIschemic Attack, TransientAntibodies, AntiphospholipidAnticoagulants

Summary

This review summarizes clinical and laboratory features, neuroimaging findings, and prognostic markers of antiphospholipid syndrome-associated ischemic stroke and TIA, and discusses evidence and uncertainties around antithrombotic therapy for secondary prevention, including anticoagulant intensity and direct oral anticoagulants.

Why This Matters for Hirudotherapy

This review summarizes the clinical and laboratory aspects of antiphospholipid syndrome (APS) associated with stroke and transient ischemic attacks, focusing on diagnostic evaluation and antithrombotic treatment strategies. It discusses the challenges of optimal anticoagulation intensity and the limited evidence base regarding the efficacy of direct oral anticoagulants for secondary prevention in this prothrombotic autoimmune disease. The abstract provides clinical practice recommendations strictly for conventional pharmacological treatments, including options for anticoagulant-refractory cases. It does not mention leeches, hirudotherapy, or the leech secretome, making its connection to the American Society of Hirudotherapy strictly indirect and limited to general thrombosis management.

Citation

Reference (Vancouver style)

Mittal P, Quattrocchi G, Tohidi-Esfahani I, Sayar Z, Chandratheva A, Cohen H. Antiphospholipid syndrome, antiphospholipid antibodies, and stroke. Int J Stroke. 2023;18(4):383-391. doi:10.1177/17474930221150349. PMID: 36571450

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.